Recent research have converged on the overlap of glucagon-like peptide-1|GIP|GCGR stimulant therapies and dopaminergic neurotransmission. While GCGR agonists are widely employed for treating type 2 diabetes mellitus, their unexpected consequences on reward circuits, specifically mediated by dopam